Spanish Academy of Dermatology and Venereology (AEDV) Melanoma Registry

The goal of this patient registry is to describe risk factors for bad prognosis of melanoma in Spain. The main questions it aims to answer are:

* To describe socioeconomical individual risk factors associated with melanoma prognosis, such as gender, residence area or socioeconomic level. * To describe potentially modifiable characteristics of health care associated with prognosis, such as waiting times, type of centre that makes the diagnosis or use of teledermatology Participants data will be gathered for analysis, without any change in the way that they are being treated.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Melanoma Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Neuroectodermal Tumors Neuroendocrine Tumors Nevi and Melanomas Skin Diseases Skin Neoplasms Skin and Connective Tissue Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All consecutive patients with a diagnosis of invasive primary cutaneous melanoma in participating centres.

Exclusion criteria

In-situ melanomas
non-cutaneous melanomas,
metastatic melanoma with unknown primary site.

Treatment and study plan

Primary outcomes

AJCC (American Joint Committee on Cancer) TNM stage (Tumor, node, metastasis)

Time frame: 1 day At diagnosis

Staging based on tumor thickness and ulceration, spread to lymph nodes and spread to distant sites.
Breslow thickness

Time frame: 1 day At diagnosis

Breslow thickness is the measurement of the depth of the melanoma from the surface of your skin down through to the deepest point of the tumour.

Secondary outcomes

Time to progression

Time frame: through study completion, an average of 3 years
Survival

Time frame: through study completion, an average of 3 years

Study contacts

Contact information is provided by the study sponsor or research team.

Ignacio Garcia-Doval, PhD

CONTACT

[email protected]

Mercè Grau, MD

CONTACT

[email protected]

34 91 544 62 84

Sponsors and collaborators

Lead sponsor

Fundación Academia Española de Dermatología

Other

Registry information

Official study title

Registro de Melanoma de la AEDV

Important dates

Study start: 2022
Primary completion: 2032
Study completion: 2032
First posted: Jan 6, 2023
Registry last updated: Jan 9, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting